Majbritt Grønborg K.
- Country
- Denmark
- Department
- Nyremedicinsk afdeling (Regionshospitalet Esbjerg Finsensgade 35 6700 Esbjerg)
Research Overview
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
- Evaluation of Prophylactic Amoxicillin/Clavulanic Acid or Clindamycin in Preventing Bloodstream Infections in Hemodialysis Patients with Central Venous Catheters
Data & Insights
Has run more than one trial at 2 of 164 partner sites.
Specializations
Renal Disease Management
The investigator specializes in treating patients with chronic kidney disease (CKD) and its associated complications, with particular attention to hypertension management in renal patients.
- Chronic Kidney Disease Progression
- Blood Pressure Control in CKD
- Glomerular Filtration Rate Assessment
Their research encompasses innovative therapeutic approaches for slowing CKD progression through combined treatment strategies.
Hemodialysis Care
This specialist focuses on optimizing care for patients requiring hemodialysis, particularly addressing complications associated with central venous catheter (CVC) access.
- Vascular Access Management
- Infection Prevention Protocols
- Blood Stream Infection Control
Their expertise includes developing preventive strategies for reducing infection risks in hemodialysis patients.
Infection Management
The investigator specializes in preventing and treating bloodstream infections in patients with renal conditions, with emphasis on prophylactic approaches in high-risk populations.
- Antibiotic Prophylaxis
- Blood Culture Analysis
- Infection Risk Assessment
Their work includes evaluating antimicrobial strategies for patients undergoing regular hemodialysis treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.